Fresenius Kabi is a leading international health care company focusing on products for the therapy and care of critically and chronically ill patients inside and outside the hospital. Fresenius Kabi develops, produces and markets pharmaceuticals and medical devices.
The product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for whole blood collection and processing as well as for transfusion medicine and cell therapies.
With ist corporate philosophy of “caring for life,” Fresenius Kabi is committed to supporting medical professionals in the best therapy of patients.
To the homepage of Fresenius Kabi
Fresenius Kabi provides:
- Infusion Therapy
- Parenteral Nutrition
- Enteral Nutrition
- Infusion Technology
- Transfusion Technology
- Ambulatory Care
Fresenius Kabi has more than 30,000 employees worldwide and a global network of around 60 sales organizations and more than 60 production sites and compounding centers. In 2012, Fresenius Kabi achieved sales of € 4,539 million and an operating profit (EBIT) of € 934 million.
Fresenius Kabi AG is a 100% subsidiary of Fresenius SE & Co. KGaA.